Although states control Medicaid payment rates, federal government members agree that providers need higher reimbursements. MedPage Today reports:
Rep. Henry Waxman (D-Calif.), the top Democrat on the House Energy and Commerce Committee, suggested Wednesday that Congress do one thing that can be done from Washington: extend the temporary payment increase Medicaid primary care providers are seeing, bringing their reimbursements on par with those of Medicare. The change impacts general pediatricians, general internists, and family physicians.
The Affordable Care Act allowed for this bump in pay for 2013 and 2014 with the federal government paying the difference, but Waxman suggested it be extended beyond next year. "Any member concerned about access to doctors for Medicaid beneficiaries should surely embrace that," he said.
Medicaid on average pays 66% of Medicare rates, Seema Verma, MPH, a health policy consultant with Strategic Health Policy Solutions in Carmel, Ind., told lawmakers at the committee hearing, entitled "The Need for Medicaid Reform."
Read the full story here: http://bit.ly/160p6R6
Accountable Care Organizations and HPV Vaccine Uptake: A Multilevel Analysis
October 24th 2024The authors evaluated whether adolescents receiving care at accountable care organizations (ACOs) vs non-ACOs were more likely to initiate and complete the human papillomavirus (HPV) vaccination series.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More